The ASH annual meeting serves as a way for the CDCN to help disseminate cutting edge Castleman disease research
Minds meet to fight Castleman disease
Each year, members of the CDCN team attend the annual American Society of Hematology Meeting to present abstracts of CDCN led Castleman disease research projects as well as to collaborate with physicians and researchers from around the world to discuss key CDCN priorities focused on patient care and the international research agenda.
This meeting is also an opportunity to disseminate best practices in Castleman disease diagnosis and treatment to practicing hematologists from around the world. At ASH, the CDCN hosts a working dinner attended by dozens of physicians and researchers from around the globe, who are dedicated to advancing the understanding and treatment of Castleman disease. The dinner serves as an opportunity for the CDCN’s network of physicians and researchers to discuss new research and set research priorities for the upcoming year.
The annual meeting at ASH is a tremendous example of the power of the CDCN’s collaborative research approach to defeating Castleman disease
2019’s ASH Meeting was held in Orlando Florida from December 7th to December 10th at the Rosen Centre. Research related to Castleman disease was showcased in the first hour of the Working Dinner. Another year another success!!!
Schedule:
Saturday, December 7, 2019
Abstracts during the Main Meeting
5:30 PM – 7:30 PM Abstract #1: “Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare” (Session 203, Abstract#1046, Orange County Convention Center, Hall B)
5:30 PM – 7:30 PM Abstract #2: “Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain” (Session 623, Abstract#1540, Orange County Convention Center, Hall B)
CDCN Working Dinner
7:00 PM – 7:30 PM Registration
7:30 PM – 9:30 PM Working Dinner, Rosen Centre (Across the street from the Orange County Convention Center, ASH Main Location) Room: Grand A.
- 7:00 – 7:30 PM. Registration and seating
- 7:40 – 7:55 Terminology, diagnosis, and treatment of CD. (Dr. Frits van Rhee)
- 7:55 – 9:05 PM. Research highlights, including submitted abstracts
- 7:55 – 8:07: Natural History Registry of CD: Spectrum/Treatment (Sheila Pierson)
- 8:07 – 8:12 A big picture of iMCD. (Dr. David Fajgenbaum)
- 8:12 – 8:24 The role of mTOR in CD. (Dr. David Fajgenbaum)
- 8:24 – 8:36 Multiomic studies on iMCD. (Ruth-Anne Langan Pai)
- 8:36 – 8:48 Longitudinal cytokine studies of iMCD. (Dr. Ana Oromendia)
- 8:48 – 9:00 TAFRO syndrome and CD, correlation and epidemiology in Japan. (Dr. Yasufumi Misaki).
- 9:00 – 9:05 Call to action
- 7:55 – 8:07: Natural History Registry of CD: Spectrum/Treatment (Sheila Pierson)
- 9:05 – 9:30 PM. Round Table Discussion.
Monday, December 9, 2019
Abstracts during the Main Meeting
6:00 PM – 8:00PM Abstract #3: ASH Poster Presentation – “Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease” (Session 203, Abstract# 3599, Orange County Convention Center, Hall B)
